Trial protocols define eligibility, endpoints, and oversight, and they can change over timeso registries are the most reliable place to verify details
Concomitant use of hydrocodone bitartrate and acetaminophen tablets with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of hydrocodone bitartrate and acetaminophen tablets and prolong opioid adverse reactions, and which may cause potentially fatal respiratory depression (see WARNINGS), particularly when an inhibitor is added after a stable dose of hydrocodone bitartrate and acetaminophen tablets is achieved
10.12729/jbtr.2020.21.3.101 55 LiM.ShaoD.ZhouJ.GuJ.QinJ.LiX.et al (2022)
Serious: Respiratory depression (most dangerous) Hypotension Confusion Risk of dependence and tolerance Withdrawal symptoms on stopping
There will be no particles and no cloudiness
Some patients notice results within weeks